We are live on ! Find out more
ONC icon

BeOne Medicines

239 hedge funds and large institutions have $10.4B invested in BeOne Medicines in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 99 increasing their positions, 79 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more call options, than puts

Call options by funds: $23.6M | Put options by funds: $14M

25% more repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 79

0.59% less ownership

Funds ownership: 54.2% → 53.61% (-0.59%)

9% less funds holding

Funds holding: 264 → 239 (-25)

17% less funds holding in top 10

Funds holding in top 10: 12 → 10 (-2)

23% less capital inflows, than outflows

Capital inflows: $490M | Capital outflows: $635M

49% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 43

Holders
239
Holders Change
-25
Holders Change %
-9.47%
% of All Funds
3.75%
Holding in Top 10
10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-16.67%
% of All Funds
0.16%
New
22
Increased
99
Reduced
79
Closed
43
Calls
$23.6M
Puts
$14M
Net Calls
+$9.7M
Net Calls Change
+$106M

ONC Hedge Fund Activity: Q1 2022 in Review

239 of the 6,366 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q1 2022, worth a combined $10.4B — down 31% from $15B a quarter earlier.

Sellers outnumbered buyers: 43 funds closed out of ONC and 22 opened new positions — a net loss of 21 holders — while 79 trimmed existing stakes and 99 added.

The largest buyer was Capital International Investors, adding an estimated $151M. The largest seller was Wellington Management Group, cutting an estimated $144M.

  • 239 institutional investors held BeOne Medicines (ONC) as of Q1 2022, down from 264 in Q4 2021.
  • Funds reported $10.4B of BeOne Medicines stock for Q1 2022, down 31% quarter-over-quarter.
  • 22 funds opened new BeOne Medicines positions in Q1 2022 and 43 closed out, a net change of -21 holders.
  • The largest BeOne Medicines buyer in Q1 2022 was Capital International Investors, an estimated $151M added.
  • The largest BeOne Medicines seller in Q1 2022 was Wellington Management Group, an estimated $144M sold.

Based on aggregated 13F filings for Q1 2022.